BidaskClub downgraded shares of Exactech (NASDAQ:EXAC) from a hold rating to a sell rating in a report issued on Thursday, February 15th.
EXAC has been the subject of a number of other reports. Sidoti downgraded shares of Exactech from a buy rating to a neutral rating in a research report on Monday, October 23rd. ValuEngine downgraded shares of Exactech from a buy rating to a hold rating in a research report on Friday, December 1st. Robert W. Baird reissued a hold rating and set a $49.00 target price on shares of Exactech in a research note on Thursday, December 7th. Gabelli cut shares of Exactech from a buy rating to a hold rating in a research note on Tuesday, October 24th. Finally, Zacks Investment Research raised shares of Exactech from a sell rating to a hold rating in a research note on Tuesday, December 26th. One analyst has rated the stock with a sell rating and five have issued a hold rating to the company. Exactech presently has a consensus rating of Hold and an average target price of $49.00.
Shares of Exactech (EXAC) remained flat at $$49.25 during mid-day trading on Thursday. 256,300 shares of the company were exchanged, compared to its average volume of 182,742. Exactech has a fifty-two week low of $23.75 and a fifty-two week high of $50.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.08 and a quick ratio of 2.09. The company has a market capitalization of $707.53, a PE ratio of 4,925.00, a price-to-earnings-growth ratio of 3.66 and a beta of 0.90.
Several hedge funds have recently modified their holdings of the company. Water Island Capital LLC acquired a new stake in Exactech during the 4th quarter worth approximately $26,772,000. Gabelli Funds LLC increased its position in shares of Exactech by 138.7% in the 4th quarter. Gabelli Funds LLC now owns 701,748 shares of the medical equipment provider’s stock valued at $34,701,000 after purchasing an additional 407,724 shares during the last quarter. Kennedy Capital Management Inc. purchased a new stake in shares of Exactech in the 4th quarter valued at approximately $17,938,000. Pentwater Capital Management LP purchased a new position in shares of Exactech in the 4th quarter valued at $12,363,000. Finally, Northpointe Capital LLC purchased a new position in shares of Exactech in the 3rd quarter valued at $5,102,000. Hedge funds and other institutional investors own 61.22% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/23/exactech-exac-lowered-to-sell-at-bidaskclub.html.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.